- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Initial trabeculectomy significantly reduces proportion of glaucoma progressing eyes: TAGS Study
At present, the only treatment for glaucoma is the reduction of intraocular pressure (IOP). Trabeculectomy is the most commonly performed surgical intervention and has been proven to be more effective than medications (drops) in achieving lower IOP. For this reason, clinical guidelines in the UK and Europe suggest that trabeculectomy be offered to patients with advanced glaucoma as the first line of treatment.
The Treatment of Advanced Glaucoma Study (TAGS) is a recently completed multicentre randomised controlled trial (RCT) comparing medical versus surgical (trabeculectomy) treatments in patients presenting with previously untreated advanced open angle glaucoma (OAG). The primary outcome was vision related quality of life (QoL) measured using the Visual Function Questionnaire 25 (VFQ-25). Recently reported results indicated no difference in this primary outcome between treatment arms for the period of the study (24 months). However, patient self-reported outcome measures have been shown to lack sensitivity in detecting visual deterioration from glaucoma.
Visual field (VF) tests are an important clinical measure in glaucoma and have been successfully used as a primary outcome in previous important glaucoma trials. In the primary report of results from TAGS, the average difference in VF mean deviation (MD) between baseline and 24 months showed no difference between the two groups, despite an average 3 mmHg difference in IOP favouring trabeculectomy. However, TAGS was designed such that series of 24-2 VFs (Humphrey Field Analyzer [HFA], Zeiss Meditec, Dublin, CA) were collected at baseline and 24 months; the main trial report did not take account of all these data.
In this study Giovanni Montesano et al conducted post-hoc analysis of VF data from a two-arm multicenter randomized controlled clinical trial. Authors applied these methods to the serial VF data from TAGs with the objective of identifying whether there is a treatment difference between the study arms not seen in the primary outcome to compare visual field (VF) progression between the two arms of the Treatment of Advanced Glaucoma Study (TAGS).
453 patients with newly diagnosed advanced open-angle glaucoma in at least one eye from 27 centers in the United Kingdom were randomized to either trabeculectomy (N = 227) or medications in their index eye (N = 226) and followed-up for two years with two 24-2 VF tests at baseline, 4, 12 and 24 months. Authors analyzed data for participants with a reliable VF (False positive rate < 15%) at baseline and at least two other time-points. Time for each eye to progress from baseline beyond specific cut-offs (0.5, 1, 1.5 and 2 dB) was compared using survival analysis.
211 eyes in the trabeculectomy-first arm and 203 eyes in the medications-first arm were analyzed. The average RoPs were -0.59 [-0.88, -0.31] dB/year in the medications-first arm and -0.40 [-0.67, -0.13] dB/year in the trabeculectomy-first arm. The difference was not significant (Bayesian p-value = 0.353). More eyes progressed in the medications first arm: ≥0.5 dB (p = 0.001), ≥1dB (p = 0.014), ≥1.5dB (p = 0.071) and ≥2dB (p = 0.061).
The main outcome did not show any statistically significant difference in the rate of VF progression in patients randomised to trabeculectomy first compared to medication first after 24 months of follow-up. Study also explored possible differences in localised progression, by analysing the average progression rate for different VF clusters, by comparing the RoP of the fastest cluster and the average RoP of the 5 fastest locations in each eye and, finally, by comparing the time to estimated perimetric blindness of individual locations. These comparisons all failed to reach significance. However, authors found a significantly higher percentage of eyes progressing beyond specific cut-offs from baseline sensitivity, indicating lower frequency of progressive VF loss in eyes receiving trabeculectomy first.
The authors concluded there was no significant difference in the average RoP at two years. Initial trabeculectomy significantly reduced the proportion of progressing eyes.
Source: Giovanni Montesano , Giovanni Ometto , Anthony King , David F. Garway-Heath , David P. Crabb , Two-year visual field outcomes of the treatment for advanced glaucoma study (TAGS), American Journal of Ophthalmology (2022),
doi: https://doi.org/10.1016/j.ajo.2022.09.011
Dr Ishan Kataria has done his MBBS from Medical College Bijapur and MS in Ophthalmology from Dr Vasant Rao Pawar Medical College, Nasik. Post completing MD, he pursuid Anterior Segment Fellowship from Sankara Eye Hospital and worked as a competent phaco and anterior segment consultant surgeon in a trust hospital in Bathinda for 2 years.He is currently pursuing Fellowship in Vitreo-Retina at Dr Sohan Singh Eye hospital Amritsar and is actively involved in various research activities under the guidance of the faculty.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751